Immunome IMNM
NASDAQ IMNM
$18.26 +0.34 (+1.93%)
As of: Oct 21, 2026 · 11:15 AM EDT

Immunome (IMNM) Non-Current Debt (2020 - 2021)

Updated

Immunome's Non-Current Debt was $134,000 in Q1 2021, unchanged from the prior quarter.

Analysis

Immunome (IMNM) Non-Current Debt (2020 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,129.91 Bn 1,098.50 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 613.69 Bn 532.22 Bn 17.26 Bn 37.34 Bn
3 AbbVie 503.05 Bn 476.16 Bn 12.70 Bn 62.48 Bn
4 Merck 367.72 Bn 322.10 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 297.87 Bn 261.86 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.30 Bn 234.99 Bn 12.86 Bn 23.68 Bn
7 Amgen 235.86 Bn 191.25 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.51 Bn 164.71 Bn 6.22 Bn 23.83 Bn
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn 60.50 Bn
10 Immunome 2.07 Bn 38.40 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 134,000.00
Dec 31, 2020 134,000.00
Sep 30, 2020 195,000.00
API Access

Immunome Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=IMNM&period=max&api_key=YOUR_API_KEY